Download PDF
Semin Thromb Hemost 2013; 39(07): 711-722
DOI: 10.1055/s-0033-1354419
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Tailored versus Standard Dose Prophylaxis in Children with Hemophilia A

Cristina Santoro
1   Division of Hematology, Department of Cellular Biotechnology and Hematology, Sapienza University of Rome, Rome, Italy
,
Erminia Baldacci
1   Division of Hematology, Department of Cellular Biotechnology and Hematology, Sapienza University of Rome, Rome, Italy
,
Caterina Mercanti
1   Division of Hematology, Department of Cellular Biotechnology and Hematology, Sapienza University of Rome, Rome, Italy
,
Maria Gabriella Mazzucconi
1   Division of Hematology, Department of Cellular Biotechnology and Hematology, Sapienza University of Rome, Rome, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
10 September 2013 (online)

    Permissions and Reprints

Abstract

Prophylaxis is universally recognized as the treatment of choice in people with hemophilia, and tailored prophylaxis is the consistent modification of the standard weight-based dosing regimen. A large number of factors guide the choice of a specific tailored regimen, and different regimens are under evaluation. Tailored low-dose frequent regimens are likely to be cost-effective, but they are less accepted by patients. Escalating dose regimens seem to be quite effective in preventing bleedings and, consequently, arthropathy, although data on long-term outcomes are still not available. Pharmacokinetic-driven approaches have been also proposed. Sensitive and validated tools able to reliably measure the different outcomes are necessary in this setting. With regard to the evaluation of arthropathy, magnetic resonance imaging and ultrasound are promising imaging techniques in detecting early joint damage. Factor VIII trough levels can be considered a measure of the efficacy of FVIII infused, although other factors influence the bleeding pattern. Global assays of coagulation could provide more complete information on the hemostatic potential of a sample and predict bleeding phenotype. These techniques are also promising for the individualization of prophylaxis regimens, potentially resulting in less frequent dosing, more comfortable and less expensive approaches.

Keywords

hemophilia A - tailored prophylaxis - children - standard prophylaxis - outcomes
 

  • References

  • 1 Coppola A, Franchini M, Tagliaferri A. Prophylaxis in people with haemophilia. Thromb Haemost 2009; 101 (4) 674-681
    PubMedGoogle Scholar
  • 2 Berntorp E, Astermark J, Björkman S , et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003; 9 (Suppl. 01) 1-4
    PubMedGoogle Scholar
  • 3 Donadel-Claeyssens S ; European Paediatric Network for Haemophilia Management. Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management). Haemophilia 2006; 12 (2) 124-127
    CrossrefPubMedGoogle Scholar
  • 4 Srivastava A, Brewer AK, Mauser-Bunschoten EP , et al; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19 (1) e1-e47
    CrossrefPubMedGoogle Scholar
  • 5 Löfqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients—a long-term follow-up. J Intern Med 1997; 241 (5) 395-400
    CrossrefPubMedGoogle Scholar
  • 6 Coppola A, Tagliaferri A, Di Capua M, Franchini M. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges. Semin Thromb Hemost 2012; 38 (1) 79-94
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Manco-Johnson MJ, Abshire TC, Shapiro AD , et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357 (6) 535-544
    CrossrefPubMedGoogle Scholar
  • 8 Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM. ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with haemophilia A (the ESPRIT study). J Thromb Haemost 2011; 9 (4) 700-710
    CrossrefPubMedGoogle Scholar
  • 9 Richards M, Williams M, Chalmers E , et al; Paediatric Working Party of the United Kingdom Haemophilia Doctors' Organisation. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol 2010; 149 (4) 498-507
    CrossrefPubMedGoogle Scholar
  • 10 Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232 (1) 25-32
    CrossrefPubMedGoogle Scholar
  • 11 Blanchette VS, Manco-Johnson M, Santagostino E, Ljung R. Optimizing factor prophylaxis for the haemophilia population: where do we stand?. Haemophilia 2004; 10 (10) (Suppl. 04) 97-104
    CrossrefPubMedGoogle Scholar
  • 12 National Hemophilia Foundation. MASAC Recommendation Concerning Prophylaxis (RegularAdministration of Clotting Factor Concentrate to Prevent Bleeding). National Hemophilia Foundation (NHF); 2007. Apr. 11. Report No.: MASAC 179.
    Google Scholar
  • 13 Gringeri A. Prospective controlled studies on prophylaxis: an Italian approach. Haemophilia 2003; 9 (9) (Suppl. 01) 38-42 , discussion 43
    PubMedGoogle Scholar
  • 14 Santagostino E, Mancuso ME. Barriers to primary prophylaxis in haemophilic children: the issue of the venous access. Blood Transfus 2008; 6 (6) (Suppl. 02) s12-s16
    PubMedGoogle Scholar
  • 15 Santagostino E, Mancuso ME. Venous access in haemophilic children: choice and management. Haemophilia 2010; 16 (16) (Suppl. 01) 20-24
    PubMedGoogle Scholar
  • 16 Santagostino E, Mancuso ME, Tripodi A , et al. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost 2010; 8 (4) 737-743
    CrossrefPubMedGoogle Scholar
  • 17 Fischer K, van der Bom JG, Molho P , et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002; 8 (6) 745-752
    CrossrefPubMedGoogle Scholar
  • 18 Aledort LM, Haschmeyer RH, Pettersson H ; The Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. J Intern Med 1994; 236 (4) 391-399
    CrossrefPubMedGoogle Scholar
  • 19 Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105 (4) 1109-1113
    CrossrefPubMedGoogle Scholar
  • 20 van den Berg HM, Fischer K, Mauser-Bunschoten EP , et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112 (3) 561-565
    CrossrefPubMedGoogle Scholar
  • 21 Collins PW. Personalized prophylaxis. Haemophilia 2012; 18 (18) (Suppl. 04) 131-135
    CrossrefPubMedGoogle Scholar
  • 22 Petrini P. What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?. Haemophilia 2001; 7 (1) 99-102
    CrossrefPubMedGoogle Scholar
  • 23 Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Hematol 1993; 30 (3) (Suppl. 02) 3-6
    PubMedGoogle Scholar
  • 24 Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res 1980; 149 (149) 153-159
    PubMedGoogle Scholar
  • 25 Feldman BM, Pai M, Rivard GE , et al; Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4 (6) 1228-1236
    CrossrefPubMedGoogle Scholar
  • 26 Manco-Johnson MJ, Abshire TC, Brown D , et al. Initial results of a randomized, prospective trial of prophylaxis to prevent joint disease in young children with factor VIII (FVIII) deficiency. Blood 2005; 106: 3
    CrossrefPubMedGoogle Scholar
  • 27 Kern M, Blanchette V, Stain AM, Einarson TR, Feldman BM. Clinical and cost implications of target joints in Canadian boys with severe hemophilia A. J Pediatr 2004; 145 (5) 628-634
    PubMedGoogle Scholar
  • 28 Srivastava A, Chuansumrit A, Chandy M, Duraiswamy G, Karagus C. Management of haemophilia in the developing world. Haemophilia 1998; 4 (4) 474-480
    CrossrefPubMedGoogle Scholar
  • 29 Blanchette VS, Babyn P, Chan A , et al. Long term (10 year) results from the Canadian hemophilia primary prophylaxis study. J Thromb Haemost 2009; 7 (Suppl. 02) 54-55
    PubMedGoogle Scholar
  • 30 Hilliard P, Zourikian N, Blanchette V , et al. Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study. J Thromb Haemost 2013; 11 (3) 460-466
    CrossrefPubMedGoogle Scholar
  • 31 Hacker MR, Funk SM, Manco-Johnson MJ. The Colorado Haemophilia Paediatric Joint Physical Examination Scale: normal values and interrater reliability. Haemophilia 2007; 13 (1) 71-78
    CrossrefPubMedGoogle Scholar
  • 32 Dempster H, Porepa M, Young N, Feldman BM. The clinical meaning of functional outcome scores in children with juvenile arthritis. Arthritis Rheum 2001; 44 (8) 1768-1774
    CrossrefPubMedGoogle Scholar
  • 33 Hang MX, Blanchette VS, Pullenayegum E, McLimont M, Feldman BM ; Canadian Hemophilia Primary Prophylaxis Study Group. Age at first joint bleed and bleeding severity in boys with severe hemophilia A: Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2011; 9 (5) 1067-1069
    CrossrefPubMedGoogle Scholar
  • 34 Valentino LA, Mamonov V, Hellmann A , et al; Prophylaxis Study Group. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012; 10 (3) 359-367
    CrossrefPubMedGoogle Scholar
  • 35 Dodd C, Watts RG. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center. Haemophilia 2012; 18 (4) 561-567
    CrossrefPubMedGoogle Scholar
  • 36 Carlsson M, Berntorp E, Björkman S, Lindvall K. Pharmacokinetic dosing in prophylactic treatment of hemophilia A. Eur J Haematol 1993; 51 (4) 247-252
    PubMedGoogle Scholar
  • 37 Carlsson M, Berntorp E, Björkman S, Lethagen A, Ljung R. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia 1997; 3: 96-101
    CrossrefPubMedGoogle Scholar
  • 38 Björkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia 2001; 7 (2) 133-139
    CrossrefPubMedGoogle Scholar
  • 39 Lindvall K, Astermark J, Björkman S , et al. Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy. Haemophilia 2012; 18 (6) 855-859
    CrossrefPubMedGoogle Scholar
  • 40 Manco-Johnson MJ, Nuss R, Funk S, Murphy J. Joint evaluation instruments for children and adults with haemophilia. Haemophilia 2000; 6 (6) 649-657
    CrossrefPubMedGoogle Scholar
  • 41 Hilliard P, Funk S, Zourikian N , et al. Hemophilia joint health score reliability study. Haemophilia 2006; 12 (5) 518-525
    CrossrefPubMedGoogle Scholar
  • 42 Feldman BM, Funk SM, Bergstrom BM , et al. Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the hemophilia joint health score. Arthritis Care Res (Hoboken) 2011; 63 (2) 223-230
    CrossrefPubMedGoogle Scholar
  • 43 Monahan PE, Doria AS, Ljung R, Jiménez-Yuste V. Optimizing joint function: new knowledge and novel tools and treatments. Haemophilia 2012; 18 (Suppl. 05) 17-26
    PubMedGoogle Scholar
  • 44 Groen W, van der Net J, Bos K , et al. Joint health and functional ability in children with haemophilia who receive intensive replacement therapy. Haemophilia 2011; 17 (5) 783-790
    PubMedGoogle Scholar
  • 45 Khawaji M, Astermark J, Berntorp E. Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life. Eur J Haematol 2012; 88 (4) 329-335
    CrossrefPubMedGoogle Scholar
  • 46 Doria AS. State-of-the-art imaging techniques for the evaluation of haemophilic arthropathy: present and future. Haemophilia 2010; 16 (Suppl. 05) 107-114
    PubMedGoogle Scholar
  • 47 Arnold WD, Hilgartner MW. Hemophilic arthropathy. Current concepts of pathogenesis and management. J Bone Joint Surg Am 1977; 59 (3) 287-305
    PubMedGoogle Scholar
  • 48 Nuss R, Kilcoyne RF, Geraghty S, Wiedel J, Manco-Johnson M. Utility of magnetic resonance imaging for management of hemophilic arthropathy in children. J Pediatr 1993; 123 (3) 388-392
    PubMedGoogle Scholar
  • 49 Kilcoyne RF, Nuss R. Radiological evaluation of hemophilic arthropathy. Semin Thromb Hemost 2003; 29 (1) 43-48
    Article in Thieme ConnectPubMedGoogle Scholar
  • 50 Kilcoyne RF, Nuss R. Radiological assessment of haemophilic arthropathy with emphasis on MRI findings. Haemophilia 2003; 9 (Suppl. 01) 57-63 , discussion 63–64
    PubMedGoogle Scholar
  • 51 Nuss R, Kilcoyne RF, Geraghty S , et al. MRI findings in haemophilic joints treated with radiosynoviorthesis with development of an MRI scale of joint damage. Haemophilia 2000; 6 (3) 162-169
    CrossrefPubMedGoogle Scholar
  • 52 Lundin B, Pettersson H, Ljung R. A new magnetic resonance imaging scoring method for assessment of haemophilic arthropathy. Haemophilia 2004; 10 (4) 383-389
    CrossrefPubMedGoogle Scholar
  • 53 Dobón M, Lucía JF, Aguilar C , et al. Value of magnetic resonance imaging for the diagnosis and follow-up of haemophilic arthropathy. Haemophilia 2003; 9 (1) 76-85
    CrossrefPubMedGoogle Scholar
  • 54 Soler R, López-Fernández F, Rodríguez E, Marini M. Hemophilic arthropathy. A scoring system for magnetic resonance imaging. Eur Radiol 2002; 12 (4) 836-843
    CrossrefPubMedGoogle Scholar
  • 55 Mathew P, Talbut DC, Frogameni A , et al. Isotopic synovectomy with P-32 in paediatric patients with haemophilia. Haemophilia 2000; 6 (5) 547-555
    CrossrefPubMedGoogle Scholar
  • 56 Funk MB, Schmidt H, Becker S , et al. Modified magnetic resonance imaging score compared with orthopaedic and radiological scores for the evaluation of haemophilic arthropathy. Haemophilia 2002; 8 (2) 98-103
    CrossrefPubMedGoogle Scholar
  • 57 Lundin B, Babyn P, Doria AS , et al; International Prophylaxis Study Group. Compatible scales for progressive and additive MRI assessments of haemophilic arthropathy. Haemophilia 2005; 11 (2) 109-115
    CrossrefPubMedGoogle Scholar
  • 58 Lundin B, Manco-Johnson ML, Ignas DM , et al; International Prophylaxis Study Group. An MRI scale for assessment of haemophilic arthropathy from the International Prophylaxis Study Group. Haemophilia 2012; 18 (6) 962-970
    CrossrefPubMedGoogle Scholar
  • 59 Kraft J, Blanchette V, Babyn P , et al. Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada. J Thromb Haemost 2012; 10 (12) 2494-2502
    CrossrefPubMedGoogle Scholar
  • 60 Collins PW, Blanchette VS, Fischer K , et al. rAHF-PFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7 (3) 413-420
    CrossrefPubMedGoogle Scholar
  • 61 Merchan EC, De Orbe A, Gago J. Ultrasound in the diagnosis of the early stages of hemophilic arthropathy of the knee. Acta Orthop Belg 1992; 58 (2) 122-125
    PubMedGoogle Scholar
  • 62 Zukotynski K, Jarrin J, Babyn PS , et al. Sonography for assessment of haemophilic arthropathy in children: a systematic protocol. Haemophilia 2007; 13 (3) 293-304
    CrossrefPubMedGoogle Scholar
  • 63 Muça-Perja M, Riva S, Grochowska B, Mangiafico L, Mago D, Gringeri A. Ultrasonography of haemophilic arthropathy. Haemophilia 2012; 18 (3) 364-368
    CrossrefPubMedGoogle Scholar
  • 64 Martinoli C, Della Casa Alberighi O, di Minno G , et al. Development and definition of a simplified scanning procedure and scoring method for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US). Thromb Haemost 2013; 109 (6) 1170-1179
    Article in Thieme ConnectPubMedGoogle Scholar
  • 65 Rubin JM, Bude RO, Carson PL, Bree RL, Adler RS. Power Doppler US: a potentially useful alternative to mean frequency-based color Doppler US. Radiology 1994; 190 (3) 853-856
    CrossrefPubMedGoogle Scholar
  • 66 Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965; (Suppl. 77) 3-132
    PubMedGoogle Scholar
  • 67 Nilsson IM. Experience with prophylaxis in Sweden. Semin Hematol 1993; 30 (3) (Suppl. 02) 16-19
    PubMedGoogle Scholar
  • 68 Young G, Sørensen B, Dargaud Y, Negrier C, Brummel-Ziedins K, Key NS. Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood 2013; 121 (11) 1944-1950
    CrossrefPubMedGoogle Scholar
  • 69 Collins PW, Björkman S, Fischer K , et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2010; 8 (2) 269-275
    CrossrefPubMedGoogle Scholar
  • 70 Ahnström J, Berntorp E, Lindvall K, Björkman S. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 2004; 10 (6) 689-697
    CrossrefPubMedGoogle Scholar
  • 71 Den Uijl IEM, Mauser Bunschoten EP, Roosendaal G , et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand?. Haemophilia 2011; 17 (6) 849-853
    CrossrefPubMedGoogle Scholar
  • 72 Collins PW, Fischer K, Morfini M, Blanchette VS, Björkman S ; International Prophylaxis Study Group Pharmacokinetics Expert Working Group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17 (1) 2-10
    CrossrefPubMedGoogle Scholar
  • 73 Björkman S. Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A. Haemophilia 2010; 16 (4) 597-605
    PubMedGoogle Scholar
  • 74 Björkman S. Evaluation of the TCIWorks Bayesian computer program for estimation of individual pharmacokinetics of FVIII. Haemophilia 2011; 17 (1) e239-e240
    CrossrefPubMedGoogle Scholar
  • 75 Björkman S, Oh M, Spotts G , et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood 2012; 119 (2) 612-618
    CrossrefPubMedGoogle Scholar
  • 76 Dargaud Y, Béguin S, Lienhart A , et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005; 93 (3) 475-480
    PubMedGoogle Scholar
  • 77 Cawthern KM, van 't Veer C, Lock JB, DiLorenzo ME, Branda RF, Mann KG. Blood coagulation in hemophilia A and hemophilia C. Blood 1998; 91 (12) 4581-4592
    PubMedGoogle Scholar
  • 78 Brummel-Ziedins KE, Branda RF, Butenas S, Mann KG. Discordant fibrin formation in hemophilia. J Thromb Haemost 2009; 7 (5) 825-832
    CrossrefPubMedGoogle Scholar
  • 79 Wolberg AS, Allen GA, Monroe DM, Hedner U, Roberts HR, Hoffman M. High dose factor VIIa improves clot structure and stability in a model of haemophilia B. Br J Haematol 2005; 131 (5) 645-655
    CrossrefPubMedGoogle Scholar
  • 80 Barrowcliffe TW, Cattaneo M, Podda GM , et al. New approaches for measuring coagulation. Haemophilia 2006; 12 (Suppl. 03) 76-81
    CrossrefPubMedGoogle Scholar
  • 81 Brummel-Ziedins KE, Whelihan MF, Gissel M, Mann KG, Rivard GE. Thrombin generation and bleeding in haemophilia A. Haemophilia 2009; 15 (5) 1118-1125
    CrossrefPubMedGoogle Scholar
  • 82 Gissel M, Whelihan MF, Ferris LA, Mann KG, Rivard GE, Brummel-Ziedins KE. The influence of prophylactic factor VIII in severe haemophilia A. Haemophilia 2012; 18 (2) 193-199
    CrossrefPubMedGoogle Scholar
  • 83 Sorensen B, Young G. Global laboratory assays in hemophilia. In: Lee C, Berntorp E, Hoots K, , ed. Textbook of Hemophilia. 2nd ed. Oxford, UK: Wiley-Blackwell; 2010: p263-268
    CrossrefGoogle Scholar
  • 84 Sørensen B, Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost 2004; 2 (1) 102-110
    CrossrefPubMedGoogle Scholar
  • 85 Chitlur M, Warrier I, Rajpurkar M , et al. Thromboelastography in children with coagulation factor deficiencies. Br J Haematol 2008; 142 (2) 250-256
    CrossrefPubMedGoogle Scholar
  • 86 Dargaud Y, Wolberg AS, Luddington R , et al. Evaluation of a standardized protocol for thrombin generation measurement using the calibrated automated thrombogram: an international multicentre study. Thromb Res 2012; 130 (6) 929-934
    CrossrefPubMedGoogle Scholar
  • 87 Chitlur M, Sorensen B, Rivard GE , et al. Standardization of thromboelastography: a report from the TEG-ROTEM working group. Haemophilia 2011; 17 (3) 532-537
    CrossrefPubMedGoogle Scholar
  • 88 von Mackensen S, Bullinger M ; Haemo-QoL Group. Development and testing of an instrument to assess the Quality of Life of Children with Haemophilia in Europe (Haemo-QoL). Haemophilia 2004; 10 (Suppl. 01) 17-25
    PubMedGoogle Scholar
  • 89 Young NL, Bradley CS, Wakefield CD, Barnard D, Blanchette VS, McCusker PJ. How well does the Canadian Haemophilia Outcomes-Kids' Life Assessment Tool (CHO-KLAT) measure the quality of life of boys with haemophilia?. Pediatr Blood Cancer 2006; 47 (3) 305-311
    CrossrefPubMedGoogle Scholar
  • 90 Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994; 37 (12) 1761-1769
    CrossrefPubMedGoogle Scholar
  • 91 Kasper CK, Dietrich SL, Rapaport SI. Hemophilia prophylaxis with factor VIII concentrate. Arch Intern Med 1970; 125 (6) 1004-1009
    CrossrefPubMedGoogle Scholar
  • 92 Risebrough N, Oh P, Blanchette V, Curtin J, Hitzler J, Feldman BM. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A. Haemophilia 2008; 14 (4) 743-752
    CrossrefPubMedGoogle Scholar
  • 93 Pipe SW. Hemophilia: new protein therapeutics. Hematology (Am Soc Hematol Educ Program) 2010; 2010: 203-209
    CrossrefPubMedGoogle Scholar